Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anticoagulant treatment].

J D Nielsen1, S E Husted, J F Lassen

  • 1Amtssygehuset i Gentofte, Københavns Amts Trombosecenter. jdn@dadlnet.dk

Ugeskrift for Laeger
|March 31, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized trial of low-dose, ultrasound-assisted thrombolysis or heparin for pulmonary embolism.

Cardiovascular research·2026
Same author

Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Neurological prognostication tools in out-of-hospital cardiac arrest patients in Danish intensive care units from 2005 to 2013.

Acta anaesthesiologica Scandinavica·2018
Same author

The incidence of pulmonary embolism during deep vein thrombosis.

Phlebology·2013
Same author

Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Comparison of disseminated intravascular coagulation in trauma with coagulopathy of trauma/acute coagulopathy of trauma-shock.

Journal of thrombosis and haemostasis : JTH·2013
Same journal

[Mosaicism as a cause of Cowden syndrome].

Ugeskrift for laeger·2026
Same journal

[Thyrotoxic crisis with cardiogenic shock].

Ugeskrift for laeger·2026
Same journal

[Mindfulness-based cognitive therapy in the treatment of depression].

Ugeskrift for laeger·2026
Same journal

[Fitness].

Ugeskrift for laeger·2026
Same journal

[Risk of developing cataract related to fluoroscopy].

Ugeskrift for laeger·2026
Same journal

[Obturator hernia with small bowel ileus presenting as hip pain in an elderly woman].

Ugeskrift for laeger·2026
See all related articles

Vitamin K antagonists (VKA) use has tripled in Denmark, driven by new indications like atrial fibrillation. Understanding patient factors is key to safe and effective anticoagulant therapy, minimizing bleeding risks.

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Public Health

Background:

  • Sales of vitamin K antagonists (VKA) in Denmark increased over threefold between 1988 and 1998.
  • This surge in VKA usage treated over 20,000 patients annually by 1998.

Purpose of the Study:

  • To examine the trends and reasons for increased VKA use.
  • To highlight the importance of understanding factors influencing VKA metabolism and patient safety.

Main Methods:

  • Analysis of VKA sales data in Denmark.
  • Review of current recommendations for initiating anticoagulant therapy.

Main Results:

  • New indications, including chronic atrial fibrillation and venous thromboembolism, are driving VKA use.

Related Experiment Videos

  • The initial phase of anticoagulant treatment carries a higher bleeding risk.
  • Commencing therapy without a loading dose may improve maintenance dose estimation.

    • Conclusions:

    • Optimal VKA regulation requires knowledge of genetic and acquired metabolic factors.
    • Informing patients about these factors at treatment initiation is crucial for minimizing complications and ensuring safe anticoagulant therapy.